Health (PRISME)

  • Presentation
  • Activities
  • Members
  • Publications

The PRISME team is composed of physicists, biochemists, biologists and radiotherapists. We specialize in multidisciplinary research aimed at developing, optimizing and controlling innovative radiotherapies, whether it be hadrontherapy or therapies using radioactive ion-emitting elements or nanoparticles. These radiotherapies aim to improve the treatment of certain cancers by increasing the effect of ionizing radiation in the tumor while minimizing its harmful effects on healthy tissues.

Our multidisciplinary approach aims to quantify, understand and predict the effect of ionizing radiation on living organisms from processes induced at extremely short times (attosecond) at small scales (atomic nucleus) to long-term consequences (years) at the patient level.
We therefore design and carry out irradiation experiments on targets ranging from molecules or cells to small animals and patient samples (tumor, blood). These experiments feed an important part of our activity which consists in modeling the effects of radiation on living organisms.

One of the innovative techniques of radiotherapy is hadrontherapy, which is to send
an ion beam on the tumors to destroy them. We are working, in particular using simulations, data processing and predictions, to improve these systems by having on-line control over irradiation using dedicated detectors. These tools also have applications in imaging.

The activities can be divided into three research areas:

Axis 1 aims to develop simulations and detectors to control patient irradiation by detecting the particles emitted during hadrontherapy treatment. These developments also offer application prospects in the field of diagnostic imaging.

Axis 2 focuses on the development of multi-scale models and simulations to describe and predict the physical, chemical and biological processes induced by irradiation. It also develops irradiation and dosimetric control means for the measurement of radiobiological effects.

Axis 3 quantifies by experiment the effects induced by irradiation with molecular, cellular, multicellular, in-vitro or in-vivo systems. It focuses on the specificities of innovative radiotherapies and the personalization of care.

PERMANENTS:

NON-PERMANENTS:

- DOCTORANTS / DOCTORAL STUDENTS:

- CHERCHEURS NON-PERMANENTS / NON-PERMANENT RESEARCHERS:
546 documents

  • Giovanna Muggiolu, Sarah Libert, Alexandra Lauret, Philippe CĂ©ruse, Christian Adrien Righini, et al.. Stratification of Head and Neck Cancers: DNA Repair Enzyme Signature to Identify Resistance and Toxicity Biomarkers. Forum de la recherche en CancĂ©rologie 2018, Apr 2018, Villeurbanne, France. ⟨hal-01990547⟩
  • Gersende Alphonse, Marie-Anne Chanrion, Micaela Cunha, Caterina Monini, Floriane Poignant, et al.. Interaction des radiations ionisantes avec les systèmes biologiques : modĂ©lisation multi-Ă©chelle pour comprendre et optimiser les radiothĂ©rapies innovantes. Forum de la recherche en CancĂ©rologie 2018, Apr 2018, Villeurbanne, France. ⟨hal-01989434⟩
  • Floriane Poignant, Benoit Gervais, Andrei Ipatov, Caterina Monini, Hela Charfi, et al.. Biophysical modelling of the radiosensitizing effect of high-Z nanoparticles. ARGENT - MSCA ITN - Advanced Radiotherapy, Generated by Exploiting Nanoprocesses and Technologies, Jan 2018, Paris, France. ⟨hal-01713385⟩
  • J. Krimmer, D. Dauvergne, J.M. LĂ©tang, E. Testa. Prompt-gamma monitoring in hadrontherapy: A review. Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2018, 878, pp.58-73. ⟨10.1016/j.nima.2017.07.063⟩. ⟨hal-01585334⟩
  • M. Fontana, D. Dauvergne, R. Della Negra, J.M. LĂ©tang, F. Mounier, et al.. Large surface gamma cameras for medical imaging: characterization of the bismuth germanate blocks. Journal of Instrumentation, 2018, 13, pp.P08018. ⟨10.1088/1748-0221/13/08/P08018⟩. ⟨hal-01871818⟩
  • BenoĂ®te Mery, Sophie Espenel, Jean-Baptiste Guy, ChloĂ© Rancoule, Alexis Vallard, et al.. Biological aspects of chondrosarcoma: Leaps and hurdles. Crit.Rev.Oncol.Hematol., 2018, 126, pp.32-36. ⟨10.1016/j.critrevonc.2018.03.009⟩. ⟨hal-01867855⟩
  • Riad Ladjohounlou, Claire Rodriguez-Lafrasse. Contribution des effets ciblĂ©s et non ciblĂ©s en radiothĂ©rapie vectorisĂ©e alpha/Auger et en radiothĂ©rapie externe. 13ème Congrès Francophone de Radiobiologie, Dec 2017, Lyon, France. ⟨hal-03133183⟩
  • Jean-Baptiste Guy, Sophie Espenel, Anne-Sophie Wozny, Priscillia Battiston-Montagne, Dominique Ardail, et al.. Ciblage des cellules souches cancĂ©reuses dans le cancer ORL: effet synergique du cetuximab Ă  l’ABT-199 en association Ă  l’irradiation photonique. 13ème Congrès Francophone de Radiobiologie, Dec 2017, Lyon, France. ⟨hal-02062244⟩
  • Floriane Poignant, Benoit Gervais, Andrei Ipatov, Hela Charfi, Caterina Monini, et al.. ModĂ©lisation biophysique de l’effet radiosensibilisant des nanoparticles Ă  Ă©lĂ©ment lourd. SIRLAF: 13ème Congrès Francophone de Radiobiologie, Dec 2017, Lyon, France. ⟨hal-01731451⟩
  • Alexandra Lauret, CĂ©line MalĂ©sys, Jonathan Lopez, Pierre Philouze, Philippe CĂ©ruse, et al.. Cellules Tumorales Circulantes : biomarqueurs prĂ©dictifs de l’échappement tumoral Ă  la radio(chimio)thĂ©rapie dans les cancers des VADS ?. SIRLAF: 13ème Congrès Francophone de Radiobiologie, Dec 2017, Lyon, France. ⟨hal-01738727⟩

Powered by HAL logo